Urology Oncology A
EAU Bladder Cancer Recurrence Risk (EORTC)
EORTC-based risk stratification for non-muscle-invasive bladder cancer (NMIBC) recurrence and progression.
References
- Sylvester RJ, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables. Eur Urol. 2006;49(3):466-475.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Mirabegron (Overactive Bladder — Elderly) · Beta-3 Adrenoceptor Agonist
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
Pathways
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.